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DNA methylation is a well-characterized epigenetic modifi-
cation that plays central roles in mammalian development, 
genomic imprinting, X-chromosome inactivation and silenc-
ing of retrotransposon elements. Aberrant DNA methylation 
pattern is a characteristic feature of cancers and associated 
with abnormal expression of oncogenes, tumor suppressor 
genes or repair genes. Ten-eleven-translocation (TET) pro-
teins are recently characterized dioxygenases that catalyze 
progressive oxidation of 5-methylcytosine to produce 5-
hydroxymethylcytosine and further oxidized derivatives. 
These oxidized methylcytosines not only potentiate DNA 
demethylation but also behave as independent epigenetic 
modifications per se. The expression or activity of TET 
proteins and DNA hydroxymethylation are highly dysregu-
lated in a wide range of cancers including hematologic and 
non-hematologic malignancies, and accumulating evi-
dence points TET proteins as a novel tumor suppressor in 
cancers. Here we review DNA demethylation-dependent 
and -independent functions of TET proteins. We also de-
scribe diverse TET loss-of-function mutations that are 
recurrently found in myeloid and lymphoid malignancies 
and their potential roles in hematopoietic transformation. 
We discuss consequences of the deficiency of individual 
Tet genes and potential compensation between different 
Tet members in mice. Possible mechanisms underlying 
facilitated oncogenic transformation of TET-deficient he-
matopoietic cells are also described. Lastly, we address 
non-mutational mechanisms that lead to suppression or 
inactivation of TET proteins in cancers. Strategies to re-
store normal 5mC oxidation status in cancers by targeting 
TET proteins may provide new avenues to expedite the 
development of promising anti-cancer agents. 
 
 
INTRODUCTION 
1 
In mammals, the DNA methylation and hydroxymethylation 
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status is dynamically regulated by the interplay between DNA 
methyltransferase (DNMT) and Ten-eleven-translocation (TET) 
family enzymes (Pastor et al., 2013; Shen et al., 2014; Suzuki 
and Bird, 2008). DNMTs carry out DNA methylation by transfer-
ring a methyl group (CH3) from S-adenosyl methionine (SAM) 
to the 5-carbon of cytosine in a CpG dinucleotide to generate 5-
methylcytosine (5mC), which takes place predominantly in a 
symmetrical manner (Fig. 1A) (Ooi et al., 2009) . DNMT3A and 
DNMT3B are called de novo DNA methyltransferases because 
they create the initial methylation marks on unmethylated sub-
strates during the early stage of embryonic development. Rep-
lication of the DNA bearing the symmetrically methylated CpG 
dinucleotides results in hemimethylated DNA strands because 
new strands are synthesized in the absence of methylation 
marks. However, DNMT1/UHRF1 complex is preferably tar-
geted to these hemimethylated regions and restores normal 
symmetrical methylation patterns, a process termed mainten-
ance methylation (Fig. 1A) (Arita et al., 2008; Avvakumov et al., 
2008; Bostick et al., 2007; Hashimoto et al., 2008; Sharif et al., 
2007). Under conditions where maintenance methylation is 
blocked by aberrant targeting, expression, or function of the 
DNMT1/UHRF1 complex, 5mC undergoes progressive, pas-
sive dilution following each round of replication (Pastor et al., 
2013; Shen et al., 2014). 
Enzymes of TET family (TET1, TET2 and TET3) belong to 
the superfamily of Fe2+- and 2-oxoglutarate (2OG)-dependent 
dioxygenases. All three TET proteins possess a highly con-
served carboxy-terminal catalytic region that is composed of a 
cysteine-rich (Cys-rich) and a double-stranded β-helix (DSBH) 
domain (Fig. 1B) (Iyer et al., 2009; 2011; Tahiliani et al., 2009). 
TET proteins modify the methylation status of DNA by catalyz-
ing consecutive oxidation of the methyl group of 5mC to form 5-
hydroxymethylcytosine (5hmC), which in turn undergoes further 
oxidation by TET proteins into 5-formylcytosine (5fC) and 5-
carboxylcytosine (5caC) (Fig. 1C) (He et al., 2011; Ito et al., 
2011; Ko et al., 2010; Tahiliani et al., 2009). These oxidized 
methylcytosines are collectively termed ‘oxi-mCs’. When ex-
pressed in cells, the catalytic region alone is capable of oxidiz-
ing 5mCs in genome. TET proteins require ferrous iron Fe2+ (as 
an essential cofactor) and 2OG (as an obligatory co-substrate) 
which bind to the highly conserved ‘His-Xaa-Asp-(Xaa)n-His’ 
motif (Xaa refers to any amino acid) and Arg residues within the 
DSBH domain, respectively (Fig. 1C) (Hu et al., 2013; Tahiliani 
et al., 2009) . Once Fe2+ and 2OG are incorporated into their 
cognate binding motifs in the active site, dioxygen (O2) binds to 
Fe2+ and oxidizes it to ferric intermediates (Fe3+), stimulating the 
oxidative decarboxylation of 2OG (to succinate and CO2) and  
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the oxidation of substrate molecules (Fig. 2) (Shen et al., 2014).  
TET1 (also known as CXXC6) and TET3 additionally have 
the amino-terminal CXXC domain that belongs to the zinc fin-
ger type DNA-binding domain. This domain preferably recog-
nizes unmethylated relative to methylated CpG dinucleotides in 
vitro and in cells (Xu et al., 2011b; 2012; Zhang et al., 2010). 
The TET2 gene does not contain exons that encode the CXXC 
domain but studies on the ontogeny of TET genes during ver-
tebrate evolution proposed that after an ancestral TET gene 
underwent triplication to give rise to three different TET para-
logs, a chromosomal inversion occurred in the TET2 gene, 
leading to the separation of the segments that encode the 
CXXC domain and catalytic domain (Iyer et al., 2009; 2011; Ko 
et al., 2013). Thus, the exon encoding ancestral CXXC domain 
of TET2 formed a distinct gene named IDAX (also known as 
CXXC4) (Fig. 1B). Similar to the linked CXXC domains of TET1 
and TET3, the IDAX CXXC domain has a high affinity for un-
methylated CpG sequences and thus is preferentially targeted 
to CpG islands (Ko et al., 2013), suggesting that TET proteins 
contribute to the maintenance of the hypomethylated status of 
CpG islands. 
The early observation of the chromosomal translocation 
t(10;11)(q22;q23) that occurs rarely in patients with acute mye-
loid leukemia (AML) and acute lymphocytic leukemia (ALL) 
revealed that TET proteins may play a role in the pathogenesis 
of hematopoietic cancers (Lorsbach et al., 2003; Ono et al., 
2002). As a result of this translocation, the segment on chro-
mosome 10 that encodes the amino-terminal region of mixed-
lineage leukemia (MLL) H3K4 methyltransferase is fused to the 
segment on chromosome 11 that encodes the DSBH domain of 
TET1 (Lorsbach et al., 2003; Ono et al., 2002). Loss-of-function 
mutations or deletions in TET2 gene are recurrent in a wide 
range of myeloid and lymphoid malignancies (Huang and Rao, 
2014; Ko et al., 2015), and hypermethylation of the TET1 pro-
moter leads to a decrease in its expression in B cell lymphoma 
(Cimmino et al., 2015). Moreover, the expression and function 
of TET proteins and/or their modulators are frequently dysregu-
lated in a wide variety of cancers (Huang and Rao, 2014; Ko et 
al., 2015), significantly impairing 5mC oxidation in the genome. 
Despite incomplete comprehension, various Tet-deficient mu-
rine models have provided valuable insights into the physiologi-
cal function of TET proteins in normal hematopoiesis together 
with their pathogenic functions in malignant hematopoiesis, 
establishing TET proteins as novel tumor suppressors that 
directly drive hematopoietic transformation upon dysregulation. 
In this review, we focus on various loss-of-function TET muta-
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Fig. 1. DNA methylation and demethy-
lation processes mediated by DNMTs 
and TET proteins. (A) DNA methylation 
refers to the transfer of the methyl group 
from S-adenosyl methoinine (SAM) to 
the 5-carbon of cytosine to yield 5mC. 
De novo DNA methyltransferases 
DNMT3A and DNMT3B originally gen-
erate 5mC marks on unmethylated CpG 
dinucleotides. Replication leads to he-
mimethylated CpG sites that are reme-
thylated by maintenance methyltransfe-
rase DNMT1. (B) Domain structure of 
the TET family proteins. TET proteins 
contain the catalytic core region that 
consists of cysteine-rich and double 
stranded β-helix (DSBH) domain. Within 
the DSBH domain, key catalytic resi-
dues that bind Fe2+ and 2-oxoglutarate 
(2OG) are present. (C) Oxidative rever-
sal of DNA methylation marks in mam-
mals. TET proteins promote both pas-
sive and active DNA demethylation. 
TET proteins oxidize 5mCs to produce 
oxi-mCs that antagonize DNA binding of 
DNMTs, promoting passive demethyla-
tion. They also facilitate active DNA 
demethylation because thymine DNA 
glycosylase (TDG) directly excise 5fC 
and 5caC, followed by base excision 
repair (BER) of the abasic site and 
replacement with an unmodified cyto-
sine. 
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tions and mechanisms leading to the dysregulation of TET 
expression and function in hematopoietic cancers. We also 
discuss the functional redundancy among different TET pro-
teins, their association with other mutations, and the potential 
mechanisms by which TET loss-of-function promotes malignant 
transformation. 
 
TET PROTEINS FACILITATE DNA DEMETHYLATION IN 
MAMMALS  
 
DNA demethylation refers to the erasure of the methyl group 
from 5mC in DNA. This process occurs through at least two 
pathways, the passive or active demethylation pathways 
(Pastor et al., 2013; Shen et al., 2014; Wu and Zhang, 2014). 
As mentioned earlier, 5mC can be removed passively if newly 
synthesized DNA strands fail to be methylated again following 
replication when DNMT1 is absent or prevented from being 
recruited to these hemimethylated sites. TET proteins poten-
tiate passive demethylation because all oxi-mCs are capable of 
interfering with maintenance methylation by antagonizing DNA 
binding of the DNMT1/UHRF1 complex, which is termed ‘oxi-
mC-facilitated passive demethylation’ (Fig. 1C) (Hashimoto et 
al., 2012; Valinluck and Sowers, 2007). 
It has long been known that the methyl group of 5mC can al-
so be removed regardless of replication, particularly in the zy-
gotic paternal genome or primordial germ cells, a process de-
noted active demethylation (Pastor et al., 2013; Shen et al., 
2014). However, the mechanism that underlies the active de-
methylation of the mammalian genome has remained enigmat-
ic until the TET enzyme function was identified recently 
(Tahiliani et al., 2009). TET proteins facilitate this replication-
independent active demethylation in conjunction with DNA re-
pair machinery (Fig. 1C); TET proteins iteratively oxidize 5mC 
to generate oxi-mCs, of which 5fC and 5caC are subject to 
removal by DNA repair enzyme thymine-DNA glycosylase 
(TDG), which triggers base excision repair that ultimately subs-
titutes the resulting abasic sites with unmodified cytosines 
(Hashimoto et al., 2013; He et al., 2011; Maiti and Drohat, 2011; 
Zhang et al., 2012). TDG typically removes the mispaired thy-
mine (generated as a result of 5mC deamination) from T:G 
mismatch but recent studies demonstrated that it also has af-
finity for 5fC and 5caC that are normally base-paired with G (He 
et al., 2011; Maiti and Drohat, 2011; Zhang et al., 2012). Addi-
tional mechanisms that are potentially implicated in the DNA 
demethylation but are relatively less characterized include de-
carboxylation of 5caC by an unidentified enzyme (Schiesser et 
al., 2012), 5mC removal by DNMT (Chen et al., 2012), and 
5hmC deamination by AID (activation-induced deaminase)/ 
APOBEC (apolipoprotein B mRNA-editing enzyme, catalytic 
polypeptide) family of cytidine deaminases followed by base 
excision repair (Guo et al., 2011). 
 
DNA DEMETHYLATION-INDEPENDENT FUNCTIONS  
OF TET PROTEINS 
 
Increasing evidence suggests that TET-generated oxi-mCs are 
not simple intermediates in DNA demethylation pathways. In-
stead, they have direct regulatory roles in gene expression by 
behaving as independent epigenetic modifications (Fig. 3). The 
extensive genome-wide mapping of oxi-mCs in various cell 
types revealed that these modified bases are strongly enriched 
at enhancers, promoters and gene bodies, with distinct effects 
on gene expression (Pastor et al., 2013; Wu and Zhang, 2014). 
In addition, 5hmC and 5fC are fairly stable bases that are di-
luted mainly through cell proliferation (Bachman et al., 2014; 
2015). Compared with unmodified cytosine, the presence of 
5hmC increased the thermodynamic stability of double-
stranded DNA (Raiber et al., 2015). In contrast, 5fC did not 
affect thermodynamic stability but induced the conformational 
change of a DNA double helix, leading to an unusual structure 
(designated as ‘F-DNA’ by the authors) with characteristic heli-
cal underwinding (Raiber et al., 2015), raising the possibility 
that 5fC may affect local DNA supercoiling and packaging and 
hence modify the DNA's capacity to accommodate proteins. 
Also, RNA polymerase II specifically recognized the 5-carboxyl 
or 5-carbonyl moieties of 5caC or 5fC, respectively, by forming 
a hydrogen bond (Wang et al., 2015a). This interaction induced 
transient Pol II pausing or stalling and reduced the rate of Pol II 
transcription elongation on gene bodies (Kellinger et al., 2012; 
Wang et al., 2015a). Moreover, all oxi-mCs were shown to be 
recognized by their unique protein readers including transcrip-
tion factors, splicing factors, DNA repair enzymes and chromatin 
remodelers (Hashimoto et al., 2014; Iurlaro et al., 2013; Spruijt et 
al., 2013) and TET proteins were also shown to interact with a  
Fig. 2. The catalytic reaction 
mediated by TET proteins. The 
catalytic residues within the 
DSBH domain bind 2OG and 
Fe2+. Incorporation of O2 yields 
ferric intermediate Fe3+, stimulat-
ing the substrate oxidation and 
oxidative decarboxylation of 
2OG. The final products of this 
process are the oxidized product 
(oxi-mCs), succinate and CO2. 
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number of cellular proteins (Ko et al., 2015; Shen et al., 2014). 
These results collectively indicate that oxi-mCs potentially func-
tion as independent epigenetic marks regardless of DNA deme-
thylation, and that the loss of these marks per se can directly 
affect expression of genes that are implicated in various as-
pects of cellular development and functions.  
 
TET LOSS-OF-FUNCTION IN HEMATOPOIETIC 
TRANSFORMATION 
 
TET1: friend or foe?  
The potential function of TET1 in oncogenesis was first sug-
gested in early studies in which TET1 was discovered as a 
partner gene that undergoes fusion with the MLL gene in rare 
cases of AML/ALL (Lorsbach et al., 2003; Ono et al., 2002). 
However, because cancer genome sequencing analyses rarely 
identified mutations in the TET1 (as well as TET3) coding se-
quences in hematologic cancers (Huang and Rao, 2014; Ko et 
al., 2015), its exact function in normal and malignant hemato-
poiesis remained unexplored until recent studies reported key 
roles of TET1 in hematopoietic transformation (Cimmino et al., 
2015; Huang et al., 2013). Interestingly, TET1 seems to have 
distinct roles depending on the types of cancers. In MLL-
rearranged leukemia, TET1 acts as an oncogene that facilitates 
leukemogenesis by being directly activated by MLL fusion pro-
teins and upregulating the expression of key oncogenic target 
genes such as Hoxa9, Meis1 and Pbx3 (Huang et al., 2013).  
By contrast, another study using mice with germline deletion 
of Tet1 showed that Tet1 may function as a tumor suppressor in 
the pathogenesis of B cell lymphoma (Cimmino et al., 2015). 
Ablation of Tet1 in mice led to lymphocytosis, enlargement of 
lymph nodes, splenomegaly, hepatomegaly, disrupted splenic 
architecture and infiltration of atypical lymphocytes into various 
organs such as the liver, lung and kidney, ultimately resulting in 
transplantable B cell lymphoma albeit at advanced age 
(Cimmino et al., 2015). Tet1 deficiency conferred a significant 
advantage on the ability of hematopoietic stem cells (HSCs) to 
reconstitute hematopoietic lineages in a cell-intrinsic manner, 
with a slight bias toward the B cell lineage. TET1 promoters 
tended to be hypermethylated and transcriptionally silenced in 
human non-Hodgkin B cell lymphoma (B-NHL). Tet1 deficiency 
significantly decreased the frequency of long-term HSCs in the 
bone marrow and induced skewing toward the B cell lineage at 
early stage as shown by an increased frequency of lymphoid-
primed multipotent progenitors (LMPPs) (Cimmino et al., 2015). 
Loss of Tet1 in hematopoietic stem/progenitor cells (HSPCs) 
altered transcriptional programs particularly for B lineage speci-
fication, chromosome maintenance, transcription and DNA 
repair. Tet1-deficient pro-B cells were able to self-renew more 
efficiently in semi-solid medium, compared with wild-type cells. 
They also displayed accumulation of DNA damage (γH2AX 
staining) presumably due to reduced expression of genes im-
plicated in DNA damage repair (Cimmino et al., 2015). Whole-
exome sequencing of the tumors that developed in Tet1-
deficient mice identified numerous co-existing mutations that 
are also recurrently found in patients with B cell lymphoma 
(Cimmino et al., 2015). However, how Tet1 plays distinct roles 
in the development of myeloid or lymphoid malignancies; how 
Tet1 loss induces alterations in the differentiation and function 
of HSCs, gene expression and DNA repair; and how these 
phenotypes are linked to oncogenic transformation remain to 
be determined. 
 
High prevalence of TET2 mutations in hematopoietic  
malignancies  
In contrast to TET1 and TET3, TET2 undergoes somatic muta-
tions very frequently in hematopoietic malignancies (Huang and 
Rao, 2014; Ko et al., 2015). Early studies showed that the 
chromosome 4q24 recurrently undergoes microscopic dele-
tions and copy number-neutral loss-of-heterozygosity (also 
referred to as uniparental disomy) in patients with various mye-
loid malignancies such as myelodysplastic syndrome (MDS), 
myeloproliferative neoplasm (MPN), acute myeloid leukemia 
(AML) and chronic myelomonocytic leukemia (CMML) 
(Delhommeau et al., 2009; Langemeijer et al., 2009; Viguie et 
al., 2005). TET2 was initially described as a tumor suppressor 
because the deleted regions on 4q24 in these patients con-
tained only TET2 gene. Somatic mutations in the TET2 coding 
Fig. 3. Oxidized methylcytosines(oxi-mCs) can function as inde-
pendent epigenetic modifications. (A) Oxi-mCs are enriched at 
DNA sequences associated with gene expression control. (B) 
5hmC and 5fC are suggested as stable modifications that are 
mainly diluted through cell proliferation. (C) 5fC induces conforma-
tional change of DNA to 'F-DNA'. (D) 5fC and 5caC interact with 
RNA polymerase II and induce a pausing or retardation during 
transcription elongation. (E-F) Physical association of oxi-mCs (E) 
and TET proteins (F) with unique cellular proteins. 
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regions were very common in patients with either a heterozyg-
ous deletion or a copy number-neutral loss of heterozygosity 
(Delhommeau et al., 2009; Langemeijer et al., 2009). Following 
these reports, extensive whole-exome sequencing was per-
formed in a wide range of myeloid malignancies and as a result, 
TET2 was established as one of the most frequently mutated 
genes in myeloid malignancies (Huang and Rao, 2014; Ko et 
al., 2015). However, the prognostic value of TET2 mutations in 
myeloid malignancies is still not clearly defined (Huang and 
Rao, 2014; Ko et al., 2015). Most of the TET2 missense muta-
tions tend to be clustered in two highly conserved regions within 
the catalytic domain, some of which are directly targeting key 
catalytic residues that interact with Fe2+ and 2OG and impair 
the normal enzymatic activity of TET2 (Ko et al., 2010). TET2 
mutations in clinical samples also correlate well with a profound 
reduction in the global level of 5hmC (Ko et al., 2010; 
Konstandin et al., 2011; Pronier et al., 2011). These results 
collectively indicate that TET2 undergoes inactivating loss-of-
function mutations during malignant myeloid transformation. 
Depending on the mutational status of TET2, myeloid cancer 
patients can be classified into two groups (i.e. 5hmChi vs. 
5hmClow groups) at the molecular level (Ko et al., 2010). Future 
studies will resolve whether these groups display any differenc-
es in disease progression or therapeutic responses, and 
whether 5hmC levels can be used as a novel diagnostic or 
prognostic marker. 
One of the prominent features of TET2 loss-of-function muta-
tions is their ability to cause developmental skewing during 
differentiation of HSPCs. CD34+ HSPCs derived from MPN 
patients bearing TET2 mutations efficiently reconstituted the 
hematopoietic system in nonobese diabetic mice with severe 
combined immunodeficiency (NOD-SCID), with a bias toward 
myeloid cells at the expense of lymphoid cells (Delhommeau et 
al., 2009). Similarly, murine and human HSPCs depleted of 
TET2 also preferentially differentiated toward mono-
cyte/macrophage lineages over the other lineages in vitro 
(Chang et al., 2014; Ko et al., 2010; 2011; Pronier et al., 2011). 
However, the molecular basis behind this biased differentiation 
is still ambiguous. 
In addition to myeloid malignancies, TET2 mutations are also 
common in lymphoid malignancies, particularly among patients 
with peripheral T cell lymphoma (PTCL) such as angioimmu-
noblastic T cell lymphoma (AITL: 33~76%) and peripheral T cell 
lymphoma, not otherwise specified (PTCL-NOS: 20~38%) 
(Lemonnier et al., 2012; Odejide et al., 2014; Quivoron et al., 
2011). These patients frequently harbor TET2 mutations to-
gether with mutations in RHOA, DNMT3A and IDH2 genes 
(Couronne et al., 2012; Lemonnier et al., 2012; Odejide et al., 
2014; Palomero et al., 2014; Sakata-Yanagimoto et al., 2014). 
TET2 mutations correlate with derivation of T follicular helper 
cells and are associated with advanced-stage diseases and 
poorer clinical outcomes (Lemonnier et al., 2012). However, 
little is known about whether TET2 mutations have any prog-
nostic value in lymphoma. Given the rare occurrence of lym-
phomas in Tet-deficient murine models, acquisition of additional 
mutations may be important to drive lymphomagenesis. The 
pathophysiologic function of TET2 mutations in lymphoma de-
velopment and the outcome of their genetic interactions with 
other mutations warrant further investigation. 
 
Lessons from murine models with individual deficiency of 
TET genes  
In order to model a human disease containing TET2 loss-of-
function mutation, various groups have generated a variety of 
murine models by either conditionally deleting critical exons of 
Tet2 or adopting insertional mutagenesis [reviewed in (Ko et al., 
2015)]. Despite distinct gene targeting strategies, all the Tet2-
disrupted mice exhibited very similar hematopoietic phenotypes 
in vivo. Deficiency of Tet2 in adult mice as well as fetal livers 
resulted in amplification of the cell fraction (known as LSK, Lin- 
c-Kit+ Sca-1+) that is enriched in HSCs (Ko et al., 2011; 
Kunimoto et al., 2012; 2014; Li et al., 2011; Moran-Crusio et al., 
2011; Quivoron et al., 2011; Shide et al., 2012). Under competi-
tive conditions, cells isolated from the bone marrow or fetal liver 
in Tet2-deficient mice were more efficient in reconstituting he-
matopoietic lineages in a cell-autonomous manner, compared 
with wild-type cells (Ko et al., 2011; Kunimoto et al., 2012; Li et 
al., 2011; Moran-Crusio et al., 2011; Quivoron et al., 2011). 
Similarly, serial transplantation of Tet2-deficient LSK CD150+ 
fetal liver cells showed augmented hematopoietic repopulation 
capacity (Kunimoto et al., 2014). Tet2 ablation seemed to in-
crease serial replating capacity of HSPCs in colony formation 
assays in vitro (Kunimoto et al., 2014; Moran-Crusio et al., 
2011; Quivoron et al., 2011). Taken together, these results imply 
that Tet2 normally restricts the expansion, differentiation and 
function of HSCs. Several studies have argued that Tet2 defi-
ciency increases HSC self-renewal. However, the term ‘self-
renewal’ is often misinterpreted in a manner that sometimes 
can be confused with ‘serial repopulating capacity’. Strictly 
speaking, HSC ‘self-renewal’ refers to the process by which 
HSCs undergo divisions to give rise to identical HSCs to perpe-
tuate themselves throughout life. Therefore, the impact of Tet2 
deficiency on HSC self-renewal has yet to be directly tested. 
More rigorous test that directly quantifies amplified HSCs, in-
stead of measuring peripheral blood chimerism, after serial 
transplantation of purified HSCs is required, as exemplified by a 
recent study that confirmed an augmented HSC self-renewal 
upon loss of Dnmt3a (Challen et al., 2012). 
Notably, both homozygous and heterozygous deletion of Tet2 
gene can predispose mice to the development of CMML-like 
myeloid disease in several models, characterized by myeloid 
hyperplasia, leukocytosis associated monocytosis and neutro-
philia, extramedullary hematopoiesis and enlargement of the 
spleen and liver (Li et al., 2011; Moran-Crusio et al., 2011; 
Quivoron et al., 2011). However, the mechanistic links between 
Tet2 loss and myeloid transformation are still lacking. Consider-
ing the increase of HSC number and repopulating capacity 
upon Tet2 deficiency, additional studies including limiting dilu-
tion assays might be of significant help to determine whether 
Tet2 deficiency promotes leukemogenesis by conferring a stem 
cell advantage on leukemia initiating cells. 
It is now generally accepted that Tet2 loss-of-function facili-
tates myeloid transformation. However, for reasons that are not 
entirely clear, only part of the Tet2-deficient mice strains sporad-
ically developed full-blown malignancy with a very long latency 
and incomplete penetrance (Huang and Rao, 2014; Ko et al., 
2015). Some strains of Tet2-deficient mice did not develop dis-
ease, implying that the deletion of Tet2 alone is not sufficient to 
drive hematopoietic malignancies (Quivoron et al., 2011). Fur-
thermore, TET2 mutations observed in elderly people with 
clonal hematopoiesis were not always associated with an overt 
hematological malignancy (Busque et al., 2012). Considering 
that TET2 mutations frequently occur at an early phase of on-
cogenesis in MDS, CMML and MPN and seem to contribute to 
clonal expansion of leukemic cells (Delhommeau et al., 2009; 
Haferlach et al., 2014; Itzykson et al., 2013; Papaemmanuil et 
al., 2013), TET2 mutations are likely to represent an early on-
cogenic event that facilitates the initiation of transformation, and 
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then the resulting TET2-mutated pre-malignant cells acquire 
additional mutations in order to progress to a more malignant 
phenotype (Huang and Rao, 2014; Ko et al., 2015), in line with 
the ‘second hit’ hypothesis in cancer development. In support of 
this hypothesis, analyses of the mutational landscape in human 
cancers showed that TET2 mutations are indeed frequently 
found in conjunction with other mutations such as mutations in 
splicing factors SRSF2, SF3B1 and ZRSR2, and the polycomb 
proteins EZH2 and ASXL1 in MDS and CMML (Gelsi-Boyer et 
al., 2010; Haferlach et al., 2014; Hanssens et al., 2014; 
Meggendorfer et al., 2012; Muto et al., 2013). They also co-
exist with KITD816V or FLT3ITD (ITD refers to internal tandem 
duplication) mutations in systemic mastocytosis (Tefferi et al., 
2009; Traina et al., 2012) or AML (Patel et al., 2012), respec-
tively. In murine models, concurrent depletion of Tet2 together 
with either Asxl1 or Ezh2 hastened the development of myeloid 
disease, recapitulating characteristics of human MDS (Abdel-
Wahab et al., 2013; Muto et al., 2013), and the co-existence of 
KITD816V or Flt3ITD led to a more aggressive form of systemic 
mastocytosis (De Vita et al., 2014) or AML (Shih et al., 2015), 
respectively. Thus, accumulation of secondary mutations in a 
TET2-deficient background may affect the disease type, pro-
gression and latency of tumorigenesis. 
Other than the expansion of HSPCs and sporadic occurrences 
of full-blown malignancy, Tet2 deficiency in mice results in rela-
tively mild hematopoietic phenotypes and all hematopoietic li-
neages differentiate normally. In murine hematopoietic cells, Tet2 
and Tet3 mRNAs are both highly expressed and their expression 
levels are dynamically regulated during differentiation (Ko et al., 
2010; Li et al., 2011; Moran-Crusio et al., 2011). Loss of either 
Tet2 or Tet3 results in merely a modest decrease in levels of 
genomic 5hmC (Ko et al., 2011; 2015). Like Tet2 deficiency, con-
ditional ablation of Tet3 with a hematopoietic-specific Vav-iCre 
transgene leads to an alteration in the frequency of HSCs and 
augments their repopulating capacity under competitive condi-
tion (Ko et al., 2015). However, the overall hematopoiesis takes 
place normally even in the absence of Tet3 (Ko et al., 2015). 
These results suggest that Tet2 and Tet3 may have overlapping 
functions and can compensate for one another. Further studies 
involving simultaneous loss of Tet2 and Tet3 in the hematopoie-
tic system will resolve this issue. 
 
POTENTIAL MECHANISMS UNDERLYING 
ONCOGENESIS DRIVEN BY TET DYSREGULATION 
 
So far, numerous studies strongly suggest that TET2 is a bona-
fide tumor suppressor in the pathogenesis of myeloid cancers. 
However, most of these studies are descriptive with no detailed 
explanation about the underlying mechanisms. It is clear that 
Tet2 deficiency not only alters homeostasis, differentiation and 
function of the HSCs, but also elevates 5mC levels at specific 
genomic loci by impairing 5mC consumption. However, whether 
these aberrations contribute to oncogenic transformation still 
remains unclear. Also, the impact of TET loss on changes of 
DNA methylation status might be more complex than we expect 
because the oxi-mCs can function independent of DNA deme-
thylation as described earlier.  
Aberrant gene expression and function are hallmarks of can-
cers and it was proposed that altered DNA methylation in TET-
deficient cells would disrupt transcriptional programs that have 
pivotal regulatory roles in normal hematopoiesis. However, 
recent global approaches that involve genome-wide mapping of 
5mC-marked regions combined with global gene expression 
profiles of wild-type and Tet-deficient embryonic stem cells or 
hematopoietic cells indicate that the changes in DNA methyla-
tion upon Tet loss do not directly account for altered patterns in 
gene expression (Challen et al., 2012; Hon et al., 2014; Huang 
et al., 2014; Lu et al., 2014). The conventional view regarding 
the abnormal DNA methylation patterns in cancers (global hy-
pomethylation and localized CpG island hypermethylation) was 
proposed mainly based on the bisulfite sequencing, which does 
not discriminate between 5mC and 5hmC (Huang et al., 2010; 
Pastor et al., 2013). Considering a substantial loss of 5hmC in 
cancers, the apparent global hypomethylation in cancers may 
reflect reduced levels of 5hmC rather than 5mC. Thus, the 
cancer-associated DNA methylation patterns and their correla-
tion with gene transcription need to be reevaluated using more 
advanced techniques that allows for genome-wide mapping of 
individual cytosine derivatives. Furthermore, the question re-
garding whether loss of TET catalytic activity, TET protein scaf-
folding function or both are responsible for hematopoietic trans-
formation is also not clearly resolved, so there remains a possi-
bility that the TET catalytic activity-independent mechanisms 
could also contribute to oncogenic transformation by altering 
chromatin architecture and gene expression through interac-
tions with various cellular proteins, which will be discussed in 
more detail in a later section. Since the identification of factors 
leading to TET dysfunction and oncogenesis remains critical for 
the development of more safe and effective cancer therapy, the 
molecular basis of oncogenesis upon loss of TET function de-
serves further exploration. 
 
NON-MUTATIONAL MECHANISMS THAT INACTIVATE 
TET PROTEINS 
 
The mechanisms of TET protein regulation are of intense inter-
est as TET protein expression and the global level of their pri-
mary catalytic product, 5hmC, is significantly diminished in 
many cancers (Huang and Rao, 2014; Ko et al., 2015). Given 
that TET proteins interact with a variety of proteins and that 
they are subject to regulation by various modulators, it is not 
surprising that the expression and activity of TET proteins can 
be targeted by non-mutational mechanisms during the onset 
and/or progression of cancers (Fig. 4). Indeed, a significant 
proportion of myeloid cancer patients who do not have somatic 
mutations in any TET genes had substantially reduced levels of 
5hmC (Ko et al., 2010; Konstandin et al., 2011; Pronier et al., 
2011), illustrating that wild-type TET proteins can become non-
functional in these cancers. Even though mutations in TET1 
and TET3 coding sequences are infrequent in hematopoietic 
malignancies, this does not necessarily mean that they are 
functional. Understanding of the various mechanisms that lead 
to the silencing of TET proteins in cancers will increase the 
options for manipulating TET activity or expression, and provide 
a more solid basis to restore normal levels of TET proteins and 
oxi-mCs in cancers, which may be beneficial for cancer therapy. 
 
Regulation of TET mRNA or protein expression  
The expression of TET proteins is regulated at multiple levels 
(Fig. 4). Mutations that lead to changes in the key regulatory 
sequences of TET genes such as promoters or enhancers can 
alter transcription by differentially regulating the recruitment of 
transcription regulators. Similarly, dysregulation of genes that 
encode essential upstream regulators can also affect TET ex-
pression. For instance, depletion of the high mobility group AT-
hook 2 (HMGA2), a chromatin remodeling factor that is highly 
expressed in some cancers but not in most normal cells, upre-
gulated TET1 expression in breast cancer cells (Sun et al., 
2013). Thereafter, TET1 stimulated the expression of its down-
stream target homeobox A (HOXA) genes by being directly  
 A Novel Tumor Suppressor Function of TET Proteins 
Jae-A Han et al. 
 
 
http://molcells.org  Mol. Cells  931 
 
 
targeted to their promoters to induce demethylation, preventing 
breast tumor growth, invasion and metastasis. Promoter CpG 
hypermethylation can also affect TET expression as reported in 
the TET1 promoter in B cell lymphomas (Cimmino et al., 2015) 
or the TET2 promoter in some gliomas and MPN (Chim et al., 
2010; Kim et al., 2011). 
Furthermore, a number of microRNAs repressed TET ex-
pression at the post-transcriptional level. One representative 
example is the oncogenic microRNA miR-22 that is highly ex-
pressed in myeloid malignancies (Song et al., 2013a; 2013b). 
Mimicking Tet2 deficiency, ectopic expression of miR-22 in mice 
led to HSC expansion and enhanced their repopulating activity 
and serial replating capacity, ultimately resulting in MDS-like 
hematopoietic malignancies that progress to myeloid leukemia 
(Song et al., 2013a). The disease phenotype was transplanta-
ble when miR-22-expressing LSK cells were transferred into 
wild-type recipient mice. The aberrant hematopoietic pheno-
types and transformation induced by miR-22 expression were 
reversed by enforced expression of Tet2, demonstrating that 
Tet2 is a central downstream target of miR-22. MiR-22 also 
reduced genomic 5hmC levels in breast cancer cells by directly 
binding to the 3’ untranslated region (3’UTR) of all TET mRNAs 
(Song et al., 2013b). Interestingly, miR-22 promoted the me-
senchymal-epithelial transition (MET), mammary tumor devel-
opment, and metastasis by downregulating TET expression, 
which in turn led to promoter methylation and suppression of 
the downstream miR-200 family members that are known to 
control various genes implicated in MET and metastasis (Song 
et al., 2013b). In another study utilizing high-throughput screen-
ing, more than 30 miRNAs including miR-125b, miR-29a, miR-
29b, miR-26a, miR-26b, miR-101 and miR-7 were shown to 
diminish TET levels (Cheng et al., 2013). Enforced expression 
of Tet2-targeting miRNAs mimicked Tet2 loss as it induced the 
expansion of myeloid lineage cells and CMML-like phenotypes, 
which was rescued by expressing Tet2 that lacks 3’UTR. Re-
pression of TET expression by miR-26a was also shown to 
promote pancreatic differentiation (Fu et al., 2013).  
TET expression is also controlled at the post-translational 
level. For example, a recent study showed that TET2 under-
goes monoubiquitylation by the CRL4VprBP complex, which in-
creases the DNA binding activity of TET2 (Nakagawa et al., 
2015). Several leukemia-associated TET2 mutations were 
shown to impair CRL4VprBP-mediated monoubiquitylation. Addi-
tionally, calpains, a family of Ca2+-dependent cysteine protei-
nases, were shown to control the steady state level of TET 
proteins in embryonic stem cells (Wang and Zhang, 2014). 
Calpain 1 (encoded by Capn1) catalyzed the proteolysis of Tet1 
and Tet2 proteins in undifferentiated embryonic stem cells, and 
calpain 2 (encoded by Capn2) degraded Tet3 in differentiated 
cells (Wang and Zhang, 2014). Interestingly, the expression of 
calpains is often aberrantly regulated in cancers. Similarly, cas-
pases, another cysteine protease similar to calpains, were also 
reported to cleave Tet proteins (Ko et al., 2013). 
 
Regulation of TET protein function 
IDH1 and IDH2 are essential components of cellular metabol-
ism that catalyze oxidative decarboxylation of isocitrate in the 
tricarboxylic acid (TCA) cycle to produce 2OG, a key interme-
diate in cellular energy metabolism. Genes encoding these 
proteins frequently undergo somatic heterozygous mutations in 
a majority of glioblastomas (~75%) and a subset of myeloid 
leukemias (~20%) or solid cancers (Abbas et al., 2010; Cairns 
et al., 2012; Gross et al., 2010; Parsons et al., 2008; Thol et al., 
2010; Yan et al., 2009). Interestingly, specific arginine residues 
in the active site of IDH enzymes (R132 in IDH1 and R140 or 
R172 in IDH2 proteins) are frequently mutated, and the result-
Fig. 4. Non-mutational mod-
ulation of TET expression and 
function. The expression and 
function of TET proteins are 
regulated on many levels. For 
details, please refer to the text.
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ing mutant IDH enzymes gain a novel enzymatic function to 
reduce 2OG to oncometabolite 2-hydroxyglutarate (2HG) 
(Dang et al., 2009; Figueroa et al., 2010; Ward et al., 2010). 
2HG functions as a potent inhibitor of TET proteins that com-
petes with 2OG in vitro and in vivo (Xu et al., 2011a). Mice ex-
pressing mutant Idh1 or Idh2 showed aberrant hematopoietic 
phenotypes such as the expansion of HSPCs, splenomegaly, 
anemia and extramedullary hematopoiesis, although IDH muta-
tions alone were not enough to drive full-blown leukemias un-
less they were combined with other mutations such as HoxA9, 
Meis1 or Flt3ITD mutations (Kats et al., 2014; Sasaki et al., 
2012). Intriguingly, continuous production of 2HG by mutant 
IDH proteins seemed to be critical for the maintenance of leu-
kemic cells as suppression of mutant IDH expression or phar-
macological inhibition of 2HG production eliminated the patho-
genic features by promoting differentiation of leukemic cells. 
Additionally, because TET proteins are critically dependent on 
the presence of co-substrates 2OG and O2 as well as a cofac-
tor Fe2+, the activity of TET proteins is sensitive to alterations in 
the levels of energy metabolites (succinate, fumarate and 2HG), 
redox status, oxygen availability and iron homeostasis. Ascor-
bate (vitamin C) is also another cofactor that is presumed to 
help maintain Fe2+ in its reduced form for full TET catalytic activ-
ity (Blaschke et al., 2013; Minor et al., 2013; Yin et al., 2013). 
TET protein function is also controlled by physical associa-
tions with other cellular proteins. A variety of proteins were 
shown to bind to TET proteins including WT1, IDAX, PGC7 and 
IkBζ (Ko et al., 2015; Shen et al., 2014). Dysregulation of these 
binding proteins can potentially lead to inactivation of TET pro-
teins by impairing their chromatin targeting. For instance, WT1 
was identified as one of key interacting partners for TET pro-
teins (Rampal et al., 2014; Wang et al., 2015b). WT1 recruited 
TET2 to specific chromatin regions, particularly promoters, to 
activate TET2 target genes and thus WT1 mutations led to 
functional inactivation of TET2, impairing TET2 target gene 
expression (Rampal et al., 2014). WT1 was also necessary for 
TET2 to suppress the growth and the colony formation of leu-
kemic cells (Wang et al., 2015b). In line with these observations, 
WT1 mutations were mutually exclusive with mutations in TET2 
and IDH genes in leukemias.  
TET2 protein levels can also be regulated through associa-
tion with another interaction partner, IDAX (Ko et al., 2013). 
IDAX was originally described as an inhibitor of the canonical 
Wnt/β-catenin signaling (Hino et al., 2001). Through a direct 
interaction, IDAX directly bound to the catalytic domain of TET2 
via its CXXC domain and seemed to recruit TET2 to chromatin 
regions with high to medium density of unmethylated CpG di-
nucleotides, such as promoters and CpG islands. Intriguingly, 
high level of IDAX led to the activation of caspases that de-
graded TET2 proteins (Ko et al., 2013). IDAX is reported to be 
dysregulated in cancers; IDAX overexpression was reported in 
villous adenomas of the colon where it would contribute to the 
depletion of 5hmCs by promoting TET2 degradation (Paez et 
al., 2014). By contrast, homozygous deletion of IDAX was re-
ported in an aggressive renal cell carcinoma (Kojima et al., 
2009). In this case, the loss of IDAX would disrupt normal ge-
nomic targeting of TET2, resulting in aberrant expression of 
TET2 target genes.  
In innate immune cells such as dendritic cells and macro-
phages, Tet2 was shown to repress Il6 transcription in the late 
phase of the lipopolysaccharide induced inflammatory re-
sponse (Zhang et al., 2015). Interestingly, Tet2 was recruited to 
the Il6 promoter by a transcription factor IkBζ, which in turn 
additionally recruited Hdac2 to induce Il6 transrepression 
through histone deacetylation. In addition to these regulatory 
mechanisms, TET3 can be localized in the cytoplasm as well 
as in the nucleus (Arioka et al., 2012; Zhang et al., 2014). 
Therefore, it is likely to be subjected to regulation by signals 
that impair nuclear translocation. However, it is unclear whether 
subcellular localization of TET3 is altered in cancers, and there-
fore future studies are required to resolve this point. 
 
CONCLUSION 
 
Epigenetic modifications are generated and erased in a highly 
dynamic and reversible manner. Therefore, genetic aberrations 
leading to epimutations that are directly implicated in the initia-
tion and progression of cancers represent an attractive target 
for cancer therapy. It is well documented that there is a direct 
causal link between TET dysregulation/mutations, impaired 
hematopoiesis and malignant hematopoietic transformation. 
Thus, it would be of great importance to assess whether mani-
pulation of 5mC oxidation status by targeting TET enzymes 
displays clinical efficacy in cancer patients. In order for these 
trials to succeed, we essentially need comprehensive under-
standing of the mechanisms that lead to the dysregulation of 
TET protein expression and activity during oncogenic transfor-
mation. Moreover, further identification of proteins or small mo-
lecules that physically or functionally interact with TET enzymes, 
together with detailed dissection of the molecular basis of their 
actions are necessary. The knowledge gained through these 
research will allow us to devise more sophisticated strategies to 
specifically manipulate TET activities, thereby facilitating the 
development of more efficient, clinically promising therapeutic 
avenues to treat human cancers. Since the inactivation of TET 
function is presumed to be a general molecular basis implicated 
in the development of diverse solid cancers including cancers 
of lung, breast, colon, intestine, prostate, liver, brain and skin, 
an anti-cancer therapy targeting TET activity will be applicable 
over a broad spectrum of human cancers. 
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